{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T16:11:55Z","timestamp":1657815115319},"reference-count":9,"publisher":"American Society of Hematology","issue":"2","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,7,14]]},"DOI":"10.1182\/blood.2022016535","type":"journal-article","created":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T15:36:39Z","timestamp":1657812999000},"page":"80-81","update-policy":"http:\/\/dx.doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["Ibrutinib frontline in young patients with CLL"],"prefix":"10.1182","volume":"140","author":[{"given":"Barbara","family":"Eichhorst","sequence":"first","affiliation":[{"name":"University of Cologne"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"2","key":"2022071415363064400_B1","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1182\/blood.2021014960","article-title":"Long-term outcomes for ibrutinib\u2013rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial","volume":"140","author":"Shanafelt","year":"2022","journal-title":"Blood"},{"issue":"18","key":"2022071415363064400_B2","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1200\/JCO.2005.12.051","article-title":"Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia","volume":"23","author":"Keating","year":"2005","journal-title":"J Clin Oncol."},{"issue":"9747","key":"2022071415363064400_B3","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial","volume":"376","author":"Hallek","year":"2010","journal-title":"Lancet."},{"issue":"3","key":"2022071415363064400_B4","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1182\/blood-2015-09-667675","article-title":"Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia","volume":"127","author":"Thompson","year":"2016","journal-title":"Blood."},{"issue":"2","key":"2022071415363064400_B5","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1182\/blood-2015-06-651125","article-title":"Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial","volume":"127","author":"Fischer","year":"2016","journal-title":"Blood."},{"key":"2022071415363064400_B6","first-page":"1","article-title":"Up to 6.5 years (median 4 years) follow-up of first-line ibruinib in patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma and high-risk genomic features: Integrated analysis of two phase 3 studies","volume":"11","author":"Burger","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"10232","key":"2022071415363064400_B7","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S0140-6736(20)30262-2","article-title":"Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial","volume":"395","author":"Sharman","year":"2020","journal-title":"Lancet."},{"issue":"5","key":"2022071415363064400_B8","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1056\/NEJMoa1817073","article-title":"Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia","volume":"381","author":"Shanafelt","year":"2019","journal-title":"N Engl J Med."},{"key":"2022071415363064400_B9","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2021-152319","article-title":"Ibrutinib plus rituximab is superior to FCR in previously untreated CLL: results of the Phase III NCRI FLAIR Trial B [abstract]","volume":"138","author":"Hillmen","year":"2021","journal-title":"Blood."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/140\/2\/80\/1906663\/bloodbld2022016535c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/140\/2\/80\/1906663\/bloodbld2022016535c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T15:36:53Z","timestamp":1657813013000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/140\/2\/80\/485800\/Ibrutinib-frontline-in-young-patients-with-CLL"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,14]]},"references-count":9,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,7,14]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2022016535","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,14]]}}}